Nicolas J Schlienz1, Tory R Spindle2, Edward J Cone2, Evan S Herrmann2, George E Bigelow2, John M Mitchell3, Ronald Flegel4, Charles LoDico4, Ryan Vandrey5. 1. Department of Psychology, University at Buffalo, 313 Diefendorf Hall, Buffalo, NY, 14214, USA. 2. Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA. 3. RTI International, 3040 East Cornwallis Road, Research Triangle Park, NC, 27709, USA. 4. Substance Abuse and Mental Health Services Administration (SAMHSA), Division of Workplace Programs (DWP), 5600 Fishers Lane, Rockville, MD, 20857, USA. 5. Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA. Electronic address: rvandrey@jhmi.edu.
Abstract
BACKGROUND: Prior controlled cannabis research has mostly focused on smoked cannabis and predominantly included frequent cannabis users. Oral cannabis products ("edibles") make up a large and growing segment of the retail cannabis market. This study sought to characterize the pharmacodynamic effects of oral cannabis among infrequent cannabis users. METHODS:Seventeen healthy adults who had not used cannabis for at least 60 days completed four experimental sessions in which they consumed a cannabis-infused brownie that contained 0, 10, 25, or 50 mg THC. Subjective effects, vital signs, cognitive/psychomotor performance, and blood THC concentrations were assessed before and for 8 h after dosing. RESULTS: Relative to placebo, the 10 mg THC dose produced discriminable subjective drug effects and elevated heart rate but did not alter cognitive/psychomotor performance. The 25 and 50 mg THC doses elicited pronounced subjective effects and markedly impaired cognitive and psychomotor functioning compared with placebo. For all active doses, pharmacodynamic effects did not manifest until 30-60 min after ingestion, and peak effects occurred 1.5-3 h post-administration. Blood THC levels were significantly correlated with some pharmacodynamic drug effects, but were substantially lower than what is typically observed after cannabis inhalation. CONCLUSION: Ingestion of oral cannabis dose-dependently altered subjective drug effects and impaired cognitive performance. Unlike inhaled forms of cannabis for which acute effects occur almost immediately, effects of oral cannabis were considerably delayed. In an era of legalization, education about the time course of drug effects for cannabis edibles is needed to facilitate dose titration and reduce acute overdose incidents.
RCT Entities:
BACKGROUND: Prior controlled cannabis research has mostly focused on smoked cannabis and predominantly included frequent cannabis users. Oral cannabis products ("edibles") make up a large and growing segment of the retail cannabis market. This study sought to characterize the pharmacodynamic effects of oral cannabis among infrequent cannabis users. METHODS: Seventeen healthy adults who had not used cannabis for at least 60 days completed four experimental sessions in which they consumed a cannabis-infused brownie that contained 0, 10, 25, or 50 mg THC. Subjective effects, vital signs, cognitive/psychomotor performance, and blood THC concentrations were assessed before and for 8 h after dosing. RESULTS: Relative to placebo, the 10 mg THC dose produced discriminable subjective drug effects and elevated heart rate but did not alter cognitive/psychomotor performance. The 25 and 50 mg THC doses elicited pronounced subjective effects and markedly impaired cognitive and psychomotor functioning compared with placebo. For all active doses, pharmacodynamic effects did not manifest until 30-60 min after ingestion, and peak effects occurred 1.5-3 h post-administration. Blood THC levels were significantly correlated with some pharmacodynamic drug effects, but were substantially lower than what is typically observed after cannabis inhalation. CONCLUSION: Ingestion of oral cannabis dose-dependently altered subjective drug effects and impaired cognitive performance. Unlike inhaled forms of cannabis for which acute effects occur almost immediately, effects of oral cannabis were considerably delayed. In an era of legalization, education about the time course of drug effects for cannabis edibles is needed to facilitate dose titration and reduce acute overdose incidents.
Authors: Caroline A MacCallum; Lindsay A Lo; Carly A Pistawka; April Christiansen; Michael Boivin; Melissa Snider-Adler Journal: Front Psychiatry Date: 2022-06-24 Impact factor: 5.435
Authors: Priscila D Gonçalves; Sarah Gutkind; Luis E Segura; João M Castaldelli-Maia; Silvia S Martins; Pia M Mauro Journal: Am J Prev Med Date: 2022-02-08 Impact factor: 6.604
Authors: Sarah L Withey; Brian D Kangas; Sophia Charles; Andrew B Gumbert; Jessica E Eisold; Susan R George; Jack Bergman; Bertha K Madras Journal: Drug Alcohol Depend Date: 2021-02-17 Impact factor: 4.492
Authors: Jamie F Burr; Christian P Cheung; Andreas M Kasper; Scott H Gillham; Graeme L Close Journal: Sports Med Date: 2021-09-13 Impact factor: 11.136
Authors: Jodi M Gilman; William A Schmitt; Kevin Potter; Brian Kendzior; Gladys N Pachas; Sarah Hickey; Meena Makary; Marilyn A Huestis; A Eden Evins Journal: Neuropsychopharmacology Date: 2022-01-08 Impact factor: 8.294
Authors: C Austin Zamarripa; Matthew D Novak; Elise M Weerts; Ryan Vandrey; Tory R Spindle Journal: Front Pharmacol Date: 2022-09-06 Impact factor: 5.988
Authors: Dennis J Sholler; Justin C Strickland; Tory R Spindle; Elise M Weerts; Ryan Vandrey Journal: Addict Biol Date: 2020-09-28 Impact factor: 4.280
Authors: Tory R Spindle; Erin L Martin; Megan Grabenauer; Thomas Woodward; Michael A Milburn; Ryan Vandrey Journal: J Psychopharmacol Date: 2021-05-28 Impact factor: 4.562